Evidence map›Paper›PMID 42936108›Full record

ArticleBioactive materials2027

Mitochondria-rich cytochalasomes as an intravenously deliverable vesicle platform for ischemic heart disease.

Xiong Gao, Lu Zhang, Lei Xu, Yawei Jin, Benheng Qian, Yuning Zhang, Mohan Li, Ze Yuan, Yihua Lu, Nan Qiu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiong GaoDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Lu ZhangDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Lei XuDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Yawei JinDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Benheng QianDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Yuning ZhangDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Mohan LiDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Ze YuanDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Yihua LuDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Nan QiuDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Peng WangDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Xiaolei SunDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Junbo GeDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.
Aijun SunDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Qidong-Fudan Innovative Institute of Medical Sciences, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poor organelle viability and rapid immune clearance limit mitochondrial transplantation for ischemic disease. Here, we engineer mitochondria-rich cytochalasomes (MRCs) as an intravenously deliverable vesicle platform. MRCs are generated through cytoskeletal remodeling in mesenchymal stem cells. They encapsulate functional mitochondria, protecting them from extracellular stressors and inheriting immunomodulatory proteins, which reduce macrophage phagocytosis by more than sixfold. Mechanistically, MRCs do not fuse with the host mitochondrial network but instead are trafficked to lysosomes and trigger protective autophagy-lysosomal response. In a murine myocardial ischemia/reperfusion (I/R) model, a single intravenous injection of MRCs reduced infarct size by 52% and preserved cardiac function for up to 28 days, whereas isolated mitochondria were ineffective. This work positions MRCs as a promising intravenously deliverable vesicle platform for ischemic heart disease and reveals a non-fusogenic mechanism.

Indexed as

AutophagyEndothelial protectionExtracellular vesiclesMitochondrial transplantationMitochondria-rich cytochalasomesMyocardial ischemia/reperfusion injury

Identifiers

PMID42936108
PMCPMC13696767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.